| 1 | la fe valencia spain | | | | | | | 2 | 0.66% |
| 2 | hospital universitario y politécnnico | | | | | | | 2 | 0.66% |
| 3 | english български ceština dansk | | | | | | | 1 | 0.33% |
| 4 | primage platform implements the | | | | | | | 1 | 0.33% |
| 5 | childhood and the diffuse | | | | | | | 1 | 0.33% |
| 6 | and the diffuse intrinsic | | | | | | | 1 | 0.33% |
| 7 | pontine glioma dipg the | | | | | | | 1 | 0.33% |
| 8 | glioma dipg the leading | | | | | | | 1 | 0.33% |
| 9 | dipg the leading cause | | | | | | | 1 | 0.33% |
| 10 | the leading cause of | | | | | | | 1 | 0.33% |
| 11 | leading cause of brain | | | | | | | 1 | 0.33% |
| 12 | cause of brain tumourrelated | | | | | | | 1 | 0.33% |
| 13 | of brain tumourrelated death | | | | | | | 1 | 0.33% |
| 14 | brain tumourrelated death in | | | | | | | 1 | 0.33% |
| 15 | children primage platform implements | | | | | | | 1 | 0.33% |
| 16 | platform implements the latest | | | | | | | 1 | 0.33% |
| 17 | of early childhood and | | | | | | | 1 | 0.33% |
| 18 | implements the latest advancement | | | | | | | 1 | 0.33% |
| 19 | the latest advancement of | | | | | | | 1 | 0.33% |
| 20 | insilico imaging biomarkers and | | | | | | | 1 | 0.33% |
| 21 | imaging biomarkers and modelling | | | | | | | 1 | 0.33% |
| 22 | biomarkers and modelling of | | | | | | | 1 | 0.33% |
| 23 | and modelling of tumour | | | | | | | 1 | 0.33% |
| 24 | modelling of tumour growth | | | | | | | 1 | 0.33% |
| 25 | of tumour growth towards | | | | | | | 1 | 0.33% |
| 26 | tumour growth towards a | | | | | | | 1 | 0.33% |
| 27 | personalised diagnosis prognosis and | | | | | | | 1 | 0.33% |
| 28 | diagnosis prognosis and therapies | | | | | | | 1 | 0.33% |
| 29 | prognosis and therapies followup | | | | | | | 1 | 0.33% |
| 30 | early childhood and the | | | | | | | 1 | 0.33% |
| 31 | cancer of early childhood | | | | | | | 1 | 0.33% |
| 32 | therapies followup tweets by | | | | | | 1 | 0.33% |
| 33 | this project proposes an | | | | | | | 1 | 0.33% |
| 34 | in insilico technologies and | | | | | | | 1 | 0.33% |
| 35 | insilico technologies and clinical | | | | | | | 1 | 0.33% |
| 36 | technologies and clinical experts | | | | | | | 1 | 0.33% |
| 37 | and clinical experts in | | | | | | | 1 | 0.33% |
| 38 | clinical experts in pediatric | | | | | | | 1 | 0.33% |
| 39 | cancer are part of | | | | | | | 1 | 0.33% |
| 40 | are part of the | | | | | | | 1 | 0.33% |